FindTrial
Sign In

RAPA-201 Rapamycin Resistant T Cells

BIOLOGICAL2 trials

Sponsors

Rapa Therapeutics LLC

Conditions

Esophageal Squamous Cell CarcinomaHead and Neck CancerMalignant MelanomaMalignant Melanoma Stage IIIcMalignant Melanoma Stage IVMalignant Melanoma With MetastasisSmall Cell and Non-small Cell Lung CancerSolid Tumor

Phase 1

RAPA-201 Therapy of Solid Tumors
RecruitingNCT05144698
Rapa Therapeutics LLCEsophageal Squamous Cell Carcinoma, Head and Neck Cancer, Malignant Melanoma +6
Start: 2021-08-01End: 2026-12-31Target: 37Updated: 2025-05-14

Phase 2

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Not yet recruitingNCT06708455
Rapa Therapeutics LLCMalignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV +1
Start: 2027-03-01End: 2029-09-30Target: 65Updated: 2026-03-19

Related Papers

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
Journal for ImmunoTherapy of Cancer2025-01-011 citations
1028 Ex vivo chemotherapy resistance of metabolically reprogrammed autologous Th1/Tc1 cells (RAPA-201): Towards the clinical translation of immune-sparing host conditioning
Regular and Young Investigator Award Abstracts2023-10-31
723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning
Regular and Young Investigator Award Abstracts2023-10-31